Targeting the androgen receptor pathway in prostate cancer
نویسندگان
چکیده
منابع مشابه
The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
Prostate cancer treatment has evolved through the varying eras of therapy from one of predominantly hormonal agents without much effective cytotoxic therapy until the use of docetaxel was found to improve overall survival in the pivotal TAX-327 (1) and SWOG 99-16 trials (2). While efforts to search for the appropriate docetaxel partner has yielded disappointing results with multiple Phase III t...
متن کاملCCR New Strategies New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
Recent data report that abiraterone acetate, a specific inhibitor of CYP17 that is key to androgen and estrogen synthesis, improves survival in metastatic castration-resistant prostate cancer (CRPC), confirming the continued dependency of CRPC on the androgen receptor (AR) signaling pathway.MDV3100 is a novel antagonist of AR that is also in phase III clinical trials. In addition, several other...
متن کاملNew strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
Recent data report that abiraterone acetate, a specific inhibitor of CYP17 that is key to androgen and estrogen synthesis, improves survival in metastatic castration-resistant prostate cancer (CRPC), confirming the continued dependency of CRPC on the androgen receptor (AR) signaling pathway. MDV3100 is a novel antagonist of AR that is also in phase III clinical trials. In addition, several othe...
متن کاملTargeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ...
متن کاملTargeting continued androgen receptor signaling in prostate cancer.
Prostate cancer is the most common cancer and the second leading cause of death from cancer in males in most Western countries. Prostate cancer has an exquisite sensitivity to androgen deprivation therapy and is the most endocrine-sensitive solid neoplasm, although advanced disease eventually progresses to castration-resistant prostate cancer (CRPC). Recent evidence has shown that cancer progre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Pharmacology
سال: 2008
ISSN: 1471-4892
DOI: 10.1016/j.coph.2008.07.005